Finance & Capital Markets

41. Fed Funding: Creative Capital Generation With James Thomas Coates, Ph.D. 8/1/2022

    As biotech capital markets continue to restrict access to funding for emerging biopharmas, you might be surprised by how many federal dollars get left on the negotiating table. To that end, James Thomas Coates, Ph.D. and his team at Decisive Point have carved out a niche in the venture capital space.

42. The Generalist Biotech CEO With Seekyo's Oury Chetboun 7/30/2025

    On this week's Business Of Biotech episode, Oury Chetboun, co-founder and CEO of Seekyo, a French biotech, talks about the range of experiences that prepared him to lead a company focused on developing innovative solid tumor treatments that target functional proteins in the tumor micro-environment.

43. Biotech Capital Markets Forecast With Allan Shaw 1/23/2022

    As Allan Shaw likes to say, "there have never been so many people with their hands out, and there has never been so much money to go around." But how sustainable is this seemingly perennial boom in the biotech capital markets? Will the road go on forever and the party never end, or are there signs of a slowdown on the horizon? Shaw once again joins us to break down the market activity he's seeing, and what he anticipates for early-stage biotech leaders in 2022. 

44. How To Be A CFO With Insmed's Sara Bonstein 4/9/2025

    On today's episode of the Business of Biotech, we're speaking with Sara Bonstein, Chief Financial Officer at Insmed, about what it takes to be a successful CFO. Sara provides useful insights on how to lead teams, especially when those teams have deeper subject matter expertise.

45. Building A Biotech Hub With Intellia Therapeutics' John Leonard, M.D. 1/13/2024

    We spend a lot of time talking with our guests about building biotech companies. That’s true of this episode too, but today we’re taking a step further with John Leonard, M.D., longtime CEO at Intellia Therapeutics.

46. The Legend Steve Gorlin's Golden Rules 11/1/2023

    Shortly after Thalidomide became a household word—albeit a very, very bad one—a biotech investor bought it for a couple hundred grand. Who on earth would want a drug pulled from the market for causing birth defects? Steve Gorlin did.

47. CDMO + Emerging Bio Partnership With Forge's John Maslowski And Ray's Jenny Holt 10/25/2023

    What constitutes a healthy, productive, and successful relationship between an emerging biopharma company and its contract development and manufacturing outsourcer (CDMO)? Jenny Holt, Chief Development Officer at the biopharma company Ray Therapeutics has some opinions. So does John Maslowski, Chief Commercial Officer at the CDMO Forge Biologics. Think they align?

48. Athersys' Ivor Macleod On Bringing Big-League Financial Experience To An Emerging Biotech 8/13/2020

    The Business Of Biotech "Summer Executive Sessions" kick off with a candid conversation with Athersys CFO Ivor Macleod, who brings years of finance leadership at Roche, Merck, and other big pharmas to Athersys as the company readies its lead candidate for life beyond clinical trials. Join us for a discussion on how Macleod is applying big-league finance principles to an emerging biopharma company, and what he's learned about managing funds in a pre-commercial biotech environment.

49. Episode 3: The Biopharma Exit Strategy With Dr. Francois Nader 8/13/2020

    Every new, emerging biopharma company shares a common goal: creating value for its employees, its board, its investors, and ultimately, patients. Along the way, that value creating might get a boost from an IPO, a merger, an acquisition, or steady growth as a private entity. On this episode of The Business Of Biotech, we talk with Dr. Francois Nader—a man who's orchestrated several wildly successful biotech exits—about why it's imperative to begin with the end in mind, and how to navigate your options when the time is right.

50. From Bayer To Startup Bio With AltruBio's Dr. Judy Chou 9/20/2021

    Judy Chou, Ph.D. was a big-pharma MVP. She earned her academic stripes in the hallowed halls of Yale, the Max Planck Institute, and Harvard Medical School before taking on principal scientist roles at AbbVie, Pfizer, and Genentech. That experience parlayed into SVP positions at Tanvex, Medvation, back to Pfizer, and on to Bayer, where she was most recently SVP and Global Head of Biotech before taking the leap into the startup scene as President & CEO at AltruBio in 2020. On today's episode of the Business of Biotech, Dr. Chou shares personal and professional insight into how she's applied what she learned in Big Bio to transform a clinical-stage developer of mAbs designed to treat a broad range of immunological diseases.